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Although the pathogenesis of BCR--ABL1-positive acute lymphoblastic leukemia (ALL) is mainly related to the expression of
the BCR--ABL1 fusion transcript, additional cooperating genetic lesions are supposed to be involved in its development and
progression. Therefore, in an attempt to investigate the complex landscape of mutations, changes in expression proﬁles and
alternative splicing (AS) events that can be observed in such disease, the leukemia transcriptome of a BCR--ABL1-positive ALL
patient at diagnosis and at relapse was sequenced using a whole-transcriptome shotgun sequencing (RNA-Seq) approach. A
total of 13.9 and 15.8 million sequence reads was generated from de novo and relapsed samples, respectively, and aligned to
the human genome reference sequence. This led to the identiﬁcation of ﬁve validated missense mutations in genes involved in
metabolic processes (DPEP1, TMEM46), transport (MVP), cell cycle regulation (ABL1) and catalytic activity (CTSZ), two of which
resulted in acquired relapse variants. In all, 6390 and 4671 putative AS events were also detected, as well as expression levels
for 18315 and 18795 genes, 28% of which were differentially expressed in the two disease phases. These data demonstrate
that RNA-Seq is a suitable approach for identifying a wide spectrum of genetic alterations potentially involved in ALL.
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INTRODUCTION
The Philadelphia (Ph) chromosome
1 arises from a reciprocal
translocation between chromosome 9 and 22
2 and it was the ﬁrst
cytogenetic abnormality linked to both chronic myeloid leukemia
and Ph-positive acute lymphoblastic leukemia. This translocation
fuses the ABL1 oncogene on chromosome 9 to a breakpoint
cluster region (BCR) from chromosome 22, generating the
constitutively activated Bcr--Abl tyrosine kinase that is responsible
for both acute and chronic diseases.
3- -5 BCR--ABL1-positive ALL
represents the most frequent and prognostically unfavorable
subtype of ALL in adults.
6 Driven by technological advances,
copy-number alterations have been identiﬁed in such disease
using single-nucleotide polymorphism (SNP) array platforms,
suggesting that additional cooperating genetic lesions are
involved in its pathogenesis.
7,8 Nowadays, high-throughput
‘next-generation sequencing technologies’, overcoming the lim-
ited scalability of traditional Sanger sequencing, are revolution-
izing genomics and transcriptomics by providing a cost-efﬁcient
and single-base resolution tool for a uniﬁed deep analysis of the
cancer complexity.
9- -12There is a vast diversity of next-generation
technologies, but these sequencing approaches generally use
massively parallel ampliﬁcation and detection strategies. The ﬁrst
whole-cancer genome sequence was reported in 2008 with the
description of the nucleotide sequence of DNA from a patient with
acute myeloid leukemia (AML) compared with DNA from normal
skin from the same patient.
13 Since then, the number of complete
sequences of cancer genomes and/or transcriptomes identiﬁed
has been rapidly growing. In the present study, Illumina
technology was used to perform a whole-transcriptome shotgun
sequencing (RNA-Seq)
9 on leukemia cells from a Phþ ALL patient
at diagnosis and at the time of hematologic, cytogenetic and
molecular relapse. A transcriptional picture of the examined
genome was drawn by mapping complementary DNA sequence
reads to the reference sequence of the human genome,
identifying expressed annotated and novel transcripts, single-
nucleotide variants (SNVs), alternative splicing (AS) events and
related absolute expression levels. A uniﬁed picture of a Phþ ALL
transcriptome was thus provided for the ﬁrst time, supporting the
belief that RNA-Seq may represent one of the most suitable
approaches to identify the genetic alterations harbored by
leukemia clones.
MATERIALS AND METHODS
The case of a 56-year-old man affected by Phþ ALL diagnosed in April
2007 is herein reported.
Double-stranded complementary DNA libraries were prepared from his
primary and relapsed RNA samples and sequenced using the Genome
Analyzer II platform, generating 36-base-pair (bp) sequence reads. These
reads were mapped to the reference sequence of the human genome
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www.nature.com/bcj(NCBI Build 36.1) using the ELAND software to assign them to exons, splice
junctions, introns/untranslated regions, external exons or intergenic
regions. Mapping reads were subsequently used for discovery of expressed
candidate SNVs by means of the BOWTIE and ERANGE software. Reads
that failed to directly align to the human genome reference sequence
were instead used to assess the splicing extent by mapping them to
an in silico-generated data set of all possible exon splice junctions.
The number of reads corresponding to RNA from known exons,
canonical splice events and new candidate genes was also estimated
and a normalized measure of gene expression level (RPKM)
11 was
computed to deﬁne gene expression proﬁles.
A full description of the examined Phþ ALL patient, as well as of
bioinformatic analyses performed to produce the described results, is
provided in the Supplementary Materials and Methods.
RESULTS
Whole-transcriptome sequencing
The RNA-Seq technique generated 13.9 and 15.8 million 36-bp
sequence reads from de novo and relapsed Phþ ALL samples,
respectively. The total number of processed reads, as well as of
those successfully mapped to the human genome reference
sequence, is shown in Table 1.
Identiﬁcation of SNVs
SNV discovery was performed by mapping the 12 million primary
ALL and 14.5 million relapse sequence reads that matched the
reference sequence of the human genome (Table 1) to all
annotated human genes and applying stringent criteria for
reducing the relative false-positive rate. The adopted ﬁlter led to
the identiﬁcation of 2011 and 2103 SNVs in the primary ALL and
relapse samples, respectively (Figure 1). Approximately 94% of
these variants have been already reported in the dbSNP build 130
(Supplementary Table S1), whereas 124 and 114 were putative
novel SNVs in the primary ALL and relapse samples, respectively.
Of these, 43 affected both samples, 81 were found only in the
primary ALL sample and 71 were relapse private substitutions
(Figure 2). These putative novel mutations were further sub-
divided into four groups according to their genomic location:
group 1 contained 60 changes located in the amino-acid-coding
regions of annotated exons, group 2 contained 38 changes
located in untranslated regions, group 3 contained 26 changes
found on annotated pseudogenes and group 4 contained 71
variants for which no information about their functional annota-
tion was available (Table 2).
As mutations affecting amino-acid-coding regions may impair
gene function, downstream analyses were focused on SNVs
belonging to group 1. From this group, mutations in human
leukocyte antigen genes, immunoglobulin heavy variable chain
genes and those in genes encoding for hypothetical proteins
Figure 1. Flow chart for identiﬁcation of somatic point mutations in the examined BCR-ABL1-positive ALL transcriptome at diagnosis and at
relapse.
Table 1. Summary of RNA-Seq genomic mapping results from the
primary and relapse BCR- -ABL1-positive ALL samples
Primary ALL Relapse
Reads processed 13913719 15782973
Aligned genomic reads
a 11999193 14467276
Unique reads
b 5265914 7470979
Multiple reads
c 6733279 6996297
Unaligned reads 1914526 1315697
AS junctions reads 25119 22859
Expressed RefSeq transcripts 18315 19796
Putative novel exons in annotated genes 6637 2541
Putative novel genes 18 23
Coverage (%) 86.24 91.66
Abbreviations: ALL, acute lymphoblastic leukemia; AS, alternative splicing;
BCR, breakpoint cluster region.
aReads mapped to the human genome
reference sequence (NCBI Build 36.1).
bReads matching with a unique
genomic location.
cReads matching with a multiple genomic location.
Whole-transcriptome sequencing of Phþ ALL
I Iacobucci et al
2
Blood Cancer Journal & 2012 Macmillan Publishers Limited(LOC728238, LOC654340, LOC285299, LOC441581, LOC644937) were
removed. This approach identiﬁed 11 non-synonymous changes:
one affecting the PLXNB2 gene on both primary ALL and relapse
samples, six affecting genes involved in metabolic processes
(PDE4DIP, EIF2S3, DPEP1, ZC3H12D, TMEM46) or transport (MVP)a t
diagnosis and two affecting genes involved in cell cycle regulation
(CDC2L1) and catalytic activity (CTSZ), as well as one affecting a
gene (CXorf21) encoding for an uncharacterized protein, at relapse
(Table 3). Furthermore, the T315I mutation in the Bcr--Abl kinase
domain, which is known to be responsible for insensitivity to
current tyrosine kinase inhibitors,
14- -16 was also identiﬁed.
Nine exons containing putative novel non-synonymous
changes were analyzed using direct Sanger sequencing
on samples collected at diagnosis, hematological remission and
relapse time. Seven SNVs identiﬁed by RNA-Seq were conﬁrmed
(Table 3 and Supplementary Figure S1), whereas two non-
synonymous changes in PDE4DIP and EIF2S3 resulted in false-
positive calls (Table 3). In accordance with RNA-seq results,
conventional Sanger sequencing conﬁrmed that the TMEM46
G59D, DPEP1 R20Q and MVP P620S mutations were speciﬁc for
diagnosis, whereas the ABL1 T315I and CTSZ R183Q were limited
to relapse, thus demonstrating that they are somatic mutations.
On the contrary, the PLXNB2 N759D and CXorf21 V230M mutations
were identiﬁed in all the examined phases of the disease
(diagnosis, hematological remission, relapse), suggesting their
germline origin. In the case of CXorf21 V230M, the Sanger
sequencing method contrasted with RNA-seq, identifying the
mutation also in the diagnosis sample.
Rare or common mutations?
To determine whether validated novel missense SNVs were
‘private’ mutations of the analyzed patient or recurrent variants
in Phþ ALL, they were investigated in 24 additional Phþ ALL
samples and two different cell lines (BV-173 and SD-1) by means
of Sanger sequencing of ampliﬁed genomic-DNA target regions.
All mutations were not conﬁrmed in this set of leukemia patients
and cell lines, with the exception of the R20Q substitution on the
DPEP1 gene. This change was identiﬁed in one of the additional
Phþ ALL patients, suggesting that it may be not a ‘private’
mutation. However, constitutional/remission DNA was not avail-
able for this additional case, preventing us from assessing whether
the R20Q mutation was an inherited alteration in such an ALL
patient.
Moreover, conﬁrmed mutated genes were searched out from a
list of 649 genes with potential roles in cancer susceptibility,
13
compiled on the basis of recently published data and the Cancer
Genome Project database (http://www.sanger.ac.uk/genetics/CGP/
Census/). Only one speciﬁc primary ALL variant and one speciﬁc
Figure 2. Venn diagram of primary ALL and relapse-detected SNVs.
Numbers in bold are putative novel SNVs, while numbers in italics
are known SNPs annotated on dbSNP Build 130.
Table 2. Putative novel SNVs detected in the primary and relapsed
BCR- -ABL1-positive ALL samples
SNV location Diagnosis
a Relapse
b Both phases
c
Coding sequences 12 29 19
Untranslated regions (UTRs) 11 17 10
Pseudogenes 4 13 9
Unknown 54 12 5
Total 81 71 43
Abbreviations: ALL, acute lymphoblastic leukemia; BCR, breakpoint cluster
region; SNVs, single-nucleotide variants; UTRs, untranslated regions.
aPrivate primary ALL SNVs.
bPrivate relapse SNVs.
cCommon SNVs
identiﬁed at both diagnosis and relapse.
Table 3. Putative novel non-synonymous SNVs detected in the primary and relapsed BCR- -ABL1-positive ALL samples
Chr Gene Mutation
type
AA
change
Primary
ALL wt:m
a
Relapse
wt:m
a
Validation
b UPD/
CNA
c
Mutations in
other ALL patients
1 CDC2L1 Missense V97A 16:0 7:9(21) n.a No n.a
1 PDE4DIP Missense R921Q 0:5(7) 15:0 No No n.a
6 ZC3H12D Missense P406S 0:8(15) 8:0 n.a No n.a
9 ABL1 Missense T315I 18:0 1:6(8) Yes No n.a
13 TMEM46 Missense G59D 1:8(8) 5:0 Yes No 0/24
16 DPEP1 Missense R20Q 6:11(19) 18:0 Yes No 1/24
16 MVP Missense P620S 1:5(5) 13:0 Yes No 0/24
20 CTSZ Missense R183Q 16:0 2:7(11) Yes No 0/24
22 PLXNB2 Missense N759D
d 0:9(13) 0:11(31) Yes No 0/24
X EIF2S3 Missense Q39K 4:5(14) 27:0 No No No
X CXorf21 Missense V230M
d 4:0 0:6(8) Yes
e No 0/24
Abbreviations: ALL, acute lymphoblastic leukemia; AA, amino-acid; BCR, breakpoint cluster region; Chr, chromosome; CNA, copy number alteration; n.a, not
applicable; UPD, uniparental disomy; wt, number of reads showing the wild-type allele; m, number of unique reads showing the mutated allele. SNVs in italics
are RNA-Seq false-positive calls.
aIn brackets is the number of multiple reads (i.e., reads matching the human genome reference sequence with a multiple
genomic location) showing the mutated allele.
bSanger sequencing of PCR-generated amplicons.
cDetected by means of Affymetrix SNP chip 6.0.
dInherited
variant observed in the primary, remission and relapsed genomic DNA samples.
eIn contrast with RNA-seq, this mutation was also found at diagnosis.
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already been associated with cancer susceptibility (MVP, ABL1),
even though none of the detected mutated genes were included
in a list of 41 ALL-related genes extracted from the COSMIC
database (http://www.sanger.ac.uk/genetics/CGP/cosmic/), which
includes an exhaustive collection of genes presenting recurrent
mutations in several cancer types.
Inherited polymorphisms
The Cancer Genome Project and COSMIC databases were also
investigated in search of genes that in the present study show
inherited annotated SNPs, as it has been recently suggested that
such polymorphisms, if they occur in somatically mutated genes,
may act as low-penetrance susceptibility alleles in some non-acute
lymphoblastic leukemias.
13 Of the detected annotated SNPs,
13 were represented by missense mutations; however, none of
the affected genes were included in the list of ALL-related genes
from the COSMIC database. By comparing the detected genes
with missense SNPs with the whole COSMIC list we have instead
observed that seven of them have already been found to display
also somatic mutations, whereas 14 were known cancer-related
genes, but without previously reported somatic mutations
(Supplementary Table S2).
SNP array correlation
To investigate whether somatic copy-number alterations and
uniparental-disomy events could characterize regions containing
the observed mutations, Affymetrix Genome Wide Human SNP
6.0. array data were also analyzed. None of the genes carrying
conﬁrmed non-synonymous substitutions lie within abnormal
genomic regions (Table 3).
Detection of AS events
Approximately 14 and 8% of the total number of processed reads
from the primary and relapse Phþ ALL samples failed to directly
align to the human genome reference sequence (Table 1). These
reads were mapped to an in silico data set of all possible splice
junctions, created by pairwise combination of annotated human
exons, in order to investigate potential AS events. According to
this approach, 6390 and 4671 putative AS events were identiﬁed
within 4334 and 3651 annotated transcripts (Supplementary
Figure S2), concerning 3833 and 3327 genes, which represent
21% and 17% of primary ALL and relapse expressed transcripts,
respectively.
A total of 1269 putative AS events were shared between the
primary ALL and relapse samples, whereas 80 and 73% of
them were found to be private ALL primary and relapse events.
These private putative AS events showed lower expression levels
compared to putative AS events shared between both samples,
with 93 and 91% of private ALL primary and relapse AS, which
showed a very small number of reads.
All identiﬁed alternatively spliced genes were compared with a
list of 729 cancer-related genes showing AS.
17 A total of 99 primary
ALL and 85 relapse genes were found to belong to such list, with
40 genes showing putative AS in both samples (Supplementary
Data 1). Among these latter genes, 17 (43%) had no reference to a
speciﬁc functional class according to Ingenuity pathway analysis
results (Ingenuity Systems, Redwood City, CA, USA, http://www.
ingenuity.com), whereas 11 (28%) were kinases and only 2 (5%)
were transcription regulators. As regards primary ALL and relapse,
private alternatively spliced genes, 21 (36%) and 20 (44%),
respectively, had no reference to a speciﬁc functional class, 7 (12
and 16%) were kinases, as well as 6 (10%) and 5 (11%) were
transcription regulators (Supplementary Data 1).
Exon-skipping events, in which exons are alternatively included
or spliced out of the mature mRNA, affected mostly one or few
exons, especially those involving putative AS shared between
both samples (Supplementary Figure S3).
The known AS pattern in the IKZF1 gene
7,18- -20 was detected
both at diagnosis and at relapse by this approach, supporting its
validity.
Quantitative measurement of transcripts expression
In all 12 and 14.5 million reads matched with the reference
sequence of the human genome (Table 1), ensuring a read density
sufﬁcient for quantitative gene-expression analysis.
12 These reads
were subsequently mapped to exon sequences from annotated
human genes and counted to estimate the number of reads
corresponding to RNA from each known exon or putative novel
gene. A detailed gene expression proﬁle was thus obtained, with a
normalized measure of gene expression for each transcript (RPKM;
reads per kb of gene model per million of reads). According to this
procedure, the expression of 18315 and 18795 known transcripts
was detected in the primary ALL and relapse samples, respectively
(Supplementary Data 2), showing that 62 and 64% of annotated
human genes were transcribed in the examined stages of the
disease. However, very low RPKM estimates (0.01 oRPKMo 10)
were computed for the majority of active genes (78% at diagnosis
and 73% at relapse), whereas moderate expression (10 oRPKMo
100) was observed for 20--24% of active genes and only 2--3% of
detected transcripts had high RPKM values (100oRPKMo8000)
(Figure 3).
Differential gene-expression analysis
Fisher’s exact test was used to compare read-count log ratios
derived from RPKM values to statistically validate differences
observed in gene expression levels between the primary ALL and
relapse samples.
21 Among genes for which expression was
detected in both the examined samples, 31% were differentially
expressed, 73% of which were upregulated (fold change 42,
Fisher’s exact test Po0.01 after Bonferroni correction) and 27%
were downregulated (fold change o 2, Fisher’s exact test
Po0.01 after Bonferroni correction) at relapse compared with
diagnosis (Supplementary Data 3).
A functional analysis was also carried out on differentially
regulated genes using the GeneGo software (http://www.
genego.com). In the list of the most overexpressed genes at
relapse, the most signiﬁcant GeneGo Pathway Map was the ‘Cell
cycle: the metaphase checkpoint’ pathway (P value¼3.94E
 10),
including genes such as AURORA Kinase A (AURKA), AURORA Kinase
Figure 3. Distribution of annotated human transcripts in classes of
expression level based on the RPKM estimates. n.e., not expressed;
0.01oRPKMo10, scarcely expressed; 10oRPKMo100, moderately
expressed; 100oRPKMo8000 highly expressed.
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Blood Cancer Journal & 2012 Macmillan Publishers LimitedB (AURKB), SURVIVIN (BIRC5), BUB1, RAD51, CENPA, INCENP and PLK1
(Supplementary Figure S4). The most signiﬁcant GeneGo Pathway
Map representing underexpressed genes at relapse with respect
to diagnosis was instead that of the ‘Signal transduction PKA
signaling’ (P-value¼2.60E
 07), including PDE3B, PDE4A and PDE4D
phosphodiesterases (Supplementary Figure S5).
In order to determine whether the observed differential
expression was due to a random variation in our data or due to
biologically relevant factors, some key genes (AURORA Kinase
B and SURVIVIN) were investigated in an additional set of eight
matched diagnosis-relapse BCR--ABL1-positive ALL samples
by quantitative RT-PCR analysis. A signiﬁcant difference in gene-
expression levels between diagnosis and relapse was found for
AURORA Kinase B (P¼0.04), conﬁrming RNA-seq results, whereas a
positive, but not signiﬁcant (P¼0.08), trend of overexpression at
relapse with respect to diagnosis was observed for SURVIVIN
(Supplementary Figure S6).
Moreover, in order to further validate RNA-seq results,
we performed a gene expression analysis by Affymetrix Human
Exon 1.0 ST arrays on 22 BCR--ABL1-positive ALL patients at
diagnosis and 6 patients at the relapse. A list of differentially
expressed genes (Supplementary Data 4) was obtained between
the diagnosis and relapse phases performing the analysis of
variance (ANOVA) on data from the 22 diagnosis samples versus
the six relapse samples and including genes with a P-value below
0.05. A concordance of 97% was found considering over- and
underexpressed genes at relapse with respect to diagnosis in
both the RNA-Seq and human exon 1.0 ST results. In other words,
the great majority of transcripts (140 genes) differentially
expressed in both the experiments were differentially expressed
in the same direction in the sequenced and in the additional set of
BCR--ABL1-positive ALL samples.
DISCUSSION
Phþ ALL is the most frequent and prognostically unfavorable
subtype of ALL in adults,
6,22- -24 with pathogenesis long since
shown to be closely related to the BCR--ABL1 fusion-transcript
expression. Nevertheless, high-resolution SNP array-based studies
have recently suggested that additional genetic lesions may be
involved in its development.
7 The present study marks for the
ﬁrst time the whole transcriptome of Phþ ALL cells, which was
sequenced using the RNA-Seq technique
9 in an effort to identify
as many alterations as possible. RNA-Seq overcomes the limita-
tions of array-based experiments
25,26 by providing a more
exhaustive approach that is able to draw a reliable qualitative
and quantitative picture of the transcriptome complexity. Thus,
two samples from a Phþ ALL patient at diagnosis and at the time
of hematological, cytogenetic and molecular relapse were
sequenced in search of genetic alterations that potentially
cooperate with the BCR--ABL1 fusion transcript.
RNA-Seq generated approximately 15 million of 36-bp
sequence reads from each sample, most of which successfully
mapped the reference sequence of the human genome. With the
exclusion of T315I mutation in the Bcr--Abl kinase domain,
ﬁve missense mutations were detected in the Phþ ALL cells
after applying stringent criteria to reduce the SNVs discovery
false-positive rate and validating novel substitutions by Sanger
sequencing. Three of these non-synonymous changes were found
in the primary ALL sample and affected genes involved in
metabolic processes (DPEP1, TMEM46) or transport (MVP). The role
of these alterations is not clear and no clues can be derived from
the literature as evidence of tumor association has not been
reported for most of them. The sole gene that has already been
associated with malignant disorders is MVP, encoding the major
vault protein (lung-resistance related protein) and involved in
nucleocytoplasmic transport. Overexpression of MVP is a potential
useful marker of clinical drug resistance in lung cancer. Moreover,
MVP has been described to have a role in cervical carcinoma,
affecting the non homologous end-joining repair system
and apoptosis through Ku70/80 and Bax downregulation.
27- -30
However, a point mutation in this gene has never been described
and the occurrence in a single case suggests that it could be a
‘passenger’ rare mutation in Phþ ALL. As regards the other
primary ALL speciﬁc mutations, substitution in the DPEP1 gene,
31
which encodes for a kidney membrane enzyme, was the sole gene
to be found in an additional Phþ ALL patient, although
constitutional/remission DNA was not available for this additional
case. The two validated missense mutations speciﬁc to the relapse
sample instead affected genes involved in catalytic activity (CTSZ)
and impaired drug responsiveness, such as the case of the T315I
mutation in the kinase domain of BCR--ABL1. Differences in
mutational patterns of primary ALL and relapse samples may
suggest that the leukemia clone from which relapsed cells have
been developed was not the predominant one at diagnosis
or, more plausibly, that most of the relapse-speciﬁc changes are
‘passenger’ mutations acquired by chance during Phþ ALL
progression by the clone harboring the BCR-- ABL1 T315I
mutation responsible for resistance to tyrosine kinase inhibitor
treatments.
14,32
Although a greater number of samples would be necessary for a
more stringent quantitative analysis, a detailed gene-expression
proﬁle was nonetheless obtained by taking advantage of a
normalized measure of gene expression for each transcript
(RPKM). This quantiﬁcation of transcript abundance indicated that
slightly more than 60% of annotated human genes were
transcribed in leukemia cells in both diagnosis and relapse
phases. Approximately 23% of genes for which expression was
detected by RNA-Seq in both samples were upregulated at relapse
with respect to diagnosis. Many of these genes affect cell-cycle
progression, suggesting that the loss of cell-cycle control and the
subsequent increased proliferation have a role in the disease
progression. Conversely, only 9% of active genes in both samples
were downregulated at relapse with respect to diagnosis. In
particular, transcripts belonging to the PKA signaling pathway,
such as PDE3B, PDE4A and PDE4D phosphodiesterases, turned out
to be the most overrepresented genes in such list, with differential
expression patterns, which were conﬁrmed also in the additional
set of paired diagnosis-relapse BCR--ABL1-positive ALL samples
analyzed with Human Exon 1.0 ST array. Proteins encoded by
these genes have 30,50-cyclic-AMP phosphodiesterase activity,
being directly involved in the process of cAMP degradation and
thus having the potential to modulate signal transduction in
multiple cell types.
33 Although further candidate-gene studies will
be required for an exhaustive characterization of the roles of these
differentially expressed genes, our results prove that the RNA-Seq
estimate of transcript abundance is sensitive enough to draw an
accurate differential gene-expression proﬁle and to deepen the
description of transcriptional changes potentially involved in ALL
progression.
The approximately three million sequence reads that failed to
directly align to the human genome reference sequence have
allowed us to identify thousands of putative AS events, which
have contributed to the high transcriptional complexity of Phþ
ALL primary and relapse samples. Interestingly, 144 genes
showing putative AS events were known to be cancer-related
alternatively spliced genes, of which kinases and transcription
regulators were the most represented functional classes.
As tyrosine kinases are good drug targets, the possibility that
some of the alternatively spliced kinases may be subjected to
therapeutic inhibition is clearly attractive. Unfortunately, the lack
of a comparison with RNA-Seq data from non-leukemic B cells did
not allow us to identify whether some of the observed AS events
are enriched in the malignant cells relative to normal cells.
Nevertheless, the obtained wide ALL transcriptional picture
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potential to lay the foundation for future improvement
of diagnostic and prognostic tools based on AS recognition, as
well as for the discovery of additional therapeutic targets for the
leukemia under consideration.
In the meantime that the present work was under editorial
revision, a number of papers focused on new bioinformatic
pipelines for RNA-Seq data analyses ﬂourished in literature.
In particular, several innovative tools have been developed for
the detection of AS events both at the gene
34- -36 and at the inter-
chromosomal level,
37- -41 thus enabling the reliable discovery of
gene fusions derived from genomic rearrangements that are quite
frequent in many cancer types. Although the exploitation of such
new approaches might have the potential to improve our
analyses, it was beyond the actual scope of this work and
we believe that it could be much more effective for processing
RNA-Seq data sets made up of hundreds of millions of paired-end
reads that turned out to be more suitable starting points for the
identiﬁcation of chimeric transcripts with respect to single-end
read data sets.
In conclusion, the adopted RNA-Seq approach provided, for the
ﬁrst time, an overview of a Phþ ALL transcriptome, identifying
novel mutations, changes in gene-expression levels and putative
AS events potentially involved in ALL manifestation and progres-
sion. This descriptive study demonstrates that the RNA-Seq
technique, if supported by adequate bioinformatic resources,
provides promising new opportunities for a cost-efﬁcient, single-
base resolution analysis of the transcriptome complexity of
leukemia cells, from both mutational and gene-expression
perspectives. This could lead to the identiﬁcation of novel target
candidate genes. Therefore, such an approach may represent
one of the most effective tools for discovering genetic rules of
Phþ ALL and of many other cancer types.
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